A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Ö. Türeci(BioNTech (Germany)), Martin Schüler(Essen University Hospital), Zanete Zvirbule(Riga East University Hospital), Christoph Huber(BioNTech (Germany)), Karl Dhaene, Florian Lordick(Leipzig University), Dirk Arnold(Asklepios Klinik Altona), Andrew Krivoshik(Astellas Pharma (United States)), Kai Wiechen(University of Applied Sciences Worms), Florian Bassermann(TUM Klinikum), Thomas J. Ettrich(University Hospital Ulm), J.W. Park(Astellas Pharma (United States)), Uğur Şahin(University Medical Center of the Johannes Gutenberg University Mainz), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Henning Schulze‐Bergkamen(Heidelberg University), Daniel Maurus(MerLion Pharma (Germany)), Dieter Koeberle(Kantonsspital St. Gallen), Ahsan M. Arozullah(Astellas Pharma (United States)), S-E. Al-Batran(Goethe University Frankfurt), Michael A. Gold
Annals of Oncology
June 25, 2019
10.1093/annonc/mdz199
Cited by 244

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k